SynthesisScientific reports2022
Development and validation of a hypoxia-associated signature for lung adenocarcinoma.
Synthesis in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06787053 (Selecting Hypoxic Tumours for Treatment Modification), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selecting Hypoxic Tumours for Treatment Modification
Who cites it
12 citing papers in PubMed.
- Gene Expression in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer Cells Exposed to Hypoxia.Cancers · 2025Article
- Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes.Nature communications · 2025Article
- Integrative systems-level analysis reveals a contextual crosstalk between hypoxia and global metabolism in human breast tumors.Molecular oncology · 2025Article
- A micro-metabolic rewiring assay for assessing hypoxia-associated cancer metabolic heterogeneity.Bioactive materials · 2025Article
- Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.JCO precision oncology · 2025Article
- Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.Cell genomics · 2025Article
- A novel lineage-tracing tool reveals that hypoxic tumor cells drive tumor relapse after radiotherapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025Article
- High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment.Frontiers in immunology · 2024Article
- Novel hypoxia-related gene signature for predicting prognoses that correlate with the tumor immune microenvironment in NSCLC.Frontiers in genetics · 2023Article
- The prognostic value of an immune-related gene signature and infiltrating tumor immune cells based on bioinformatics analysis in primary esophageal cancer.Journal of gastrointestinal oncology · 2022Article
- Identification of an Immune Classification and Prognostic Genes for Lung Adenocarcinoma Based on Immune Cell Signatures.Frontiers in medicine · 2022Article
- Development and Validation of a 6-Gene Hypoxia-Related Prognostic Signature For Cholangiocarcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hypoxia is common in non-small cell lung cancer (NSCLC) and an attractive therapeutic target. As hypoxia-targeting treatments are effective in patients with the most hypoxic tumours, we aimed to develop a lung adenocarcinoma (LUAD) hypoxia-related gene expression signature. RNAseq was used to identify genes significantly differentially expressed under hypoxia (1% O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.